Patients with activated NF-κB signaling (NFKBIA+) in mesenchymal niche cells had no significant difference in overall or progression-free survival in comparison to the NFKBIA− subset (Figure S2A and S2B) in this cohort of uniformly treated LR-MDS patients [4]. The gene discussed is NFKB1; the disease is myelodysplastic syndrome.